Mäcke HR - Search Results

1

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, Freitag P, Reubi JC, Müller-Brand J, Gratzl O, Mäcke HR. Merlo A, et al. Among authors: macke hr. Clin Cancer Res. 1999 May;5(5):1025-33. Clin Cancer Res. 1999. PMID: 10353735 Clinical Trial.

2

Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.

Beutler D, Avoledo P, Reubi JC, Mäcke HR, Müller-Brand J, Merlo A, Kühne T. Beutler D, et al. Among authors: macke hr. Cancer. 2005 Feb 15;103(4):869-73. doi: 10.1002/cncr.20822. Cancer. 2005. PMID: 15641034 Free article.

3

[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].

Otte A, Herrmann R, Mäcke HR, Müller-Brand J. Otte A, et al. Among authors: macke hr. Praxis (Bern 1994). 1999 Aug 15;88(31-32):1263-8. Praxis (Bern 1994). 1999. PMID: 10479965 German.

4

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. Wicki A, et al. Among authors: macke hr. Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965. Clin Cancer Res. 2007. PMID: 17575235

5

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.

Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, Müller-Brand J, Walter MA. Iten F, et al. Among authors: macke hr. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702. doi: 10.1158/1078-0432.CCR-07-0935. Clin Cancer Res. 2007. PMID: 18006770 Clinical Trial.

6

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA. Imhof A, et al. Among authors: macke hr. J Clin Oncol. 2011 Jun 10;29(17):2416-23. doi: 10.1200/JCO.2010.33.7873. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555692 Clinical Trial.

7

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A. Cordier D, et al. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. doi: 10.1007/s00259-010-1385-5. Epub 2010 Feb 16. Eur J Nucl Med Mol Imaging. 2010. PMID: 20157707 Free article. Clinical Trial.

8

Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.

Kneifel S, Bernhardt P, Uusijärvi H, Good S, Plasswilm L, Buitrago-Téllez C, Müller-Brand J, Mäcke H, Merlo A. Kneifel S, et al. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1388-95. doi: 10.1007/s00259-006-0351-8. Epub 2007 Jan 31. Eur J Nucl Med Mol Imaging. 2007. PMID: 17265035

9

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC, Mäcke HR. Eisenwiener KP, et al. Among authors: macke hr. Bioconjug Chem. 2002 May-Jun;13(3):530-41. doi: 10.1021/bc010074f. Bioconjug Chem. 2002. PMID: 12009943 Free article.

10

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. Wild D, et al. Among authors: macke hr. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47. doi: 10.1007/s00259-003-1255-5. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters